UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

Cyanotech Corporation Petitioner

v.

The Board of Trustees of the University of Illinois Patent Owner

> Case: IPR2013-00401 Patent No.: 5,527,533

PATENT OWNER'S RESPONSE TO PETITIONER'S OBJECTIONS TO EVIDENCE PURSUANT TO 37 C.F.R. §42.64

Pursuant to 37 C.F.R. § 42.64(2), Patent Owner provides this memorandum and supplemental evidence in response to Petitioner's Objections to Evidence dated March 28, 2014.

A. Objections to Foundation

Petitioner's object to Patent Owner exhibits ("POX") 2016-2020, 2022,

2024, 2025 and 2027 because "they have not been authenticated as required by

Federal Rule of Evidence (FRE) 901." A party authenticates a document by

presenting evidence sufficient to support a finding that the document is what the

party claims it to be. *See* FRE 901(a). The party must show that it has a rational basis for its claim, which it may show through circumstantial evidence. *United States v. Wadena*, 152 F.3d 831, 854 (8th Cir. Minn. 1998); see also, *Anwar v. Fairfield Greenwich Ltd.*,742 F.Supp.2d 367, 372 n.3 (S.D.N.Y. 2010) (rejecting plaintiff's argument that copies of agreements had not been properly authenticated where affiant stated that she had "review[ed]" the same). Documents that bear the parties company logo, among other identifiers, are indicative of authenticity. *See, e.g., In re Japanese Elec. Prods. Antitrust Litig.*, 723 F.2d 238, 293 (3d Cir. 1983); *FTC v. Hughes*, 710 F. Supp. 1520, 1522 (N.D. Tex. 1989). The fact that documents are located in the adverse party's production (and thus its possession) is enough to authenticate them. *See, e.g., United States v. Black*, 767 F.2d 1334, 1342 (9th Cir.), *cert. denied*, 474 U.S. 1022 (1985).

The following discussion and supplemental evidence eliminates any alleged doubts as to the authenticity of POX 2016-2020, 2022, 2024, 2025 and 2027-2031.

POX 2016

POX 2016 is a webpage published by the Macular Degeneration Association providing general information about macular degeneration that remains available on the internet. (http://macularhope.org/about-md/, last visited April 11, 2014.) This webpage describes what macular degeneration is and whom it typically affects.

POX 2017

POX 2017 is an informational article about age-related macular degeneration published by Bayer that remains available on the internet. (http://press.healthcare.bayer.com/html/pdf/presse/en/electronic_press_ki ts/vegf_trap-eye/AMD_Backgrounder_final.pdf, last visited April 11, 2014.) This article describes what ARMD is, who it typically affects, and how it can be treated.

POX 2018

POX 2018 is a press release dated January 24, 2013, from Nutrex-Hawaii, Inc. ("Nutrex"), a wholly-owned subsidiary of Petitioner, Cyanotech Corporation, published in the Digital Journal. When asked about POX 2018, Brent Bailey, the Chief Executive Office of both Nutrex and Cyanotech, testified that he had no reason to think that the press release (POX 2018) was not from Nutrex-Hawaii. (Bailey March 26, 2014 Depo. Tr. at 175:4-177:10.) The press release ends with the following statement: "About Nutrex-Hawaii Founded with the goal of harnessing the benefits of microalgae to alleviate malnutrition and promote health, Nutrex-Hawaii is a global leader in microalgae products. Learn more at Nutrex-Hawaii.com". The press release also states that Asthaxanthin is sold online at Nutrex-Hawaii.com and that members of the press can receive a free version of a book "by emailing traci(at)nutrex-hawaii(dot)com." There are numerous indicia confirming that this document was a press-release from Nutrex-Hawaii, a whollyowned subsidiary of Petitioner Cyanotech.

POX 2019

POX 2019 is the transcript of an interview of Dr. Gerald Cysewski (Chief Scientific Officer at Cyanotech) by Dr. Mercola. Dr. Cysewski testified that he was not sure on the exact date but that he definitively recalled Dr. Mercola interviewing him about the health benefits of natural asthaxanthin. (Cysewski March 7, 2014 Depo. Tr. at 43:11-44:7.) Dr. Cysweski testified that the time spent at the interview, including travel expenses, was spent as part of his job as Chief Scientific Officer at Cyanotech. (Cysewski March 7, 2014 Depo. Tr. 44:8-45:6.) Dr. Cysewski testified about the location, purpose, and substance, of the interview. (Cysewski March 7, 2014 Depo. Tr. at 43:11-50:12.) When asked about specific answer provided in POX 2019, Dr. Cysewski testified that he made the statements. (Cysewski March 7, 2014 Depo. Tr. 45:7-50:12.) The interview to which this transcript corresponds is still available via YouTube at http://www.youtube.com/watch?v=eM_R6qlnUZI (the statement for which Patent Owner's cite POX 2019 appears at 7:43) and an abbreviated version of the video is available at http://articles.mercola.com/videos.aspx (the statement for which Patent Owner's cite POX 2019 appears at 15:08).

POX 2020

POX 2020 is a printout from the website of Nutrex-Hawaii dated May 14th, 2011. The first page displays the Nutrex-Hawaii logo and the subsequent pages include "Nutrex Hawaii News". *United States v. Black*, 767 F.2d at 1342.

Indeed, Petitioner produced a document bearing the identical text as POX 2020 bearing a production number ascribed to Petitioner Cyanotech pursuant to Patent Owner's Requests for the Production of Document and Things. (*Cf.* POX 2020 with RA-00234287-293 (the text of both documents, including the date and authors, Bob Capelli and Dr. Gerald Cysewski, are identical).) RA-00234287-293 is a confidential document and has not been included as an exhibit hereto. Should Petitioner's object to the characterizations made about RA-00234287-293, Patent Owner reserves the right to supplement its response. Additionally, Dr. Cysewski identified POX 2020 as "a printout of the Nutrex-Hawaii website or a couple pages from the Nutrex-Hawaii website" and that it was an article posted on the Nutrex website. (Cysewski March 7, 2014 Depo. Tr. at 51:1-20; 86:4-6.)

POX 2022

POX 2022 is an article authored by Siri Khalsa in Nutrition News published in 2006. Mr. Capelli (Vice President of Sales and Marketing for Petitioner Cyanotech) testified that he recognized POX 2022, that the author of POX 2022 asked him for some literature and he provided it to her, that the author sent him

DOCKET A L A R M



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.